Quick Takeaways
- Srinivas Akkaraju has 9 issuer positions tracked on this page.
- Estimated disclosed ownership value: $551,332,015.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Srinivas Akkaraju
- Location
- Palo Alto, CA
- Summary
- The estimated net worth of Srinivas Akkaraju is at least $551,332,015 dollars as of 20 Feb 2026. Srinivas Akkaraju is the Director, 10%+ Owner of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $201.47M. Srinivas Akkaraju is the Director, 10%+ Owner of Kalaris Therapeutics, Inc. and owns shares of Kalaris Therapeutics, Inc. (KLRS) stock worth about $128.67M. Srinivas Akkaraju is the Director of vTv Therapeutics Inc. and owns shares of vTv Therapeutics Inc. (VTVT) stock worth about $76.4M. Srinivas Akkaraju is the Director of ALUMIS INC. and owns shares of ALUMIS INC. (ALMS) stock worth about $75.35M. Srinivas Akkaraju is the Director of Scholar Rock Holding Corp and owns shares of Scholar Rock Holding Corp (SRRK) stock worth about $69.43M. Srinivas Akkaraju is the Director of Syros Pharmaceuticals, Inc. and owns shares of Syros Pharmaceuticals, Inc. stock worth about $20.1K.
- Signature
- /s/ Adam Levy, Attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Srinivas Akkaraju and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Mineralys Therapeutics, Inc. ($201,471,033).
- Past-year value change for that position: +$14,999,993.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Srinivas Akkaraju
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | Director, 10%+ Owner | $201,471,033 | +$14,999,993 | +8% | 19 Feb 2026 |
| KLRS | Kalaris Therapeutics, Inc. | Director, 10%+ Owner | $128,667,109 | +$5,000,006 | +4% | 22 Dec 2025 |
| VTVT | vTv Therapeutics Inc. | Director | $76,395,257 | 22 Sep 2025 | ||
| ALMS | ALUMIS INC. | Director | $75,349,039 | +$19,069,487 | +34% | 09 Jan 2026 |
| SRRK | Scholar Rock Holding Corp | Director | $69,429,463 | +$19,988,986 | +40% | 07 Oct 2025 |
| SYRS | Syros Pharmaceuticals, Inc. | Director | $20,114 | 16 Sep 2024 | ||
| KDNY | CHINOOK THERAPEUTICS, INC. | Director | 11 Aug 2023 | |||
| ICPT | INTERCEPT PHARMACEUTICALS, INC. | Director | 08 Nov 2023 | |||
| JYAC | Jiya Acquisition Corp. | Director, 10%+ Owner | 23 Sep 2022 |
Insider Transactions Reported by Srinivas Akkaraju:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.